Cancer Family
Stromal Neoplasm
CI-CAN-00000360Explore in graph →
Non-malignant52 active trials2 approved drugs89 evidence items
- NCIt
- C6781
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000360Explore in graph →
Clinical trials
355 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01751919 | A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I) | completed | Phase 1 | 37 | Dong-A ST Co., Ltd.INDUSTRY | 1 | Oct 1, 2014 | clinicaltrials |
| NCT01381822 | Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors(TH-CR-410) | unknown | Phase 1 | 58 | Threshold PharmaceuticalsINDUSTRY |
| 1 |
| Apr 21, 2014 |
| clinicaltrials |
| NCT00399152 | Perifosine + Sunitinib Malate for Patients With Advanced Cancers | completed | Phase 1 | 15 | AEterna ZentarisINDUSTRY | 0 | Feb 19, 2014 | clinicaltrials |
| NCT00031681 | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) | completed | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00441155 | Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib | completed | Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 3 | May 13, 2013 | clinicaltrials |
| NCT00098579 | Doxorubicin Hydrochloride and Alvocidib in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery | completed | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2013 | clinicaltrials |
| NCT00025415 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 7, 2013 | clinicaltrials |
| NCT01270984 | Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects(Imatinib) | completed | Phase 1 | 30 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Oct 31, 2012 | clinicaltrials |
| NCT00006357 | STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 91 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Sep 24, 2012 | clinicaltrials |
| NCT00004910 | Endoscopic Placement of Metal Stents in Treating Patients With Cancer- Related Duodenal Obstruction | completed | Phase 1 / Phase 2 | — | Northwestern UniversityOTHER | 1 | Jun 6, 2012 | clinicaltrials |
| NCT00004911 | Endoscopic Placement of Metal Stent in Patients With Cancer-Related Bowel Obstruction | completed | Phase 1 / Phase 2 | — | Northwestern UniversityOTHER | 1 | Jun 6, 2012 | clinicaltrials |
| NCT00573404 | Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors | terminated | Phase 1 | 6 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Nov 16, 2011 | clinicaltrials |
| NCT00276302 | Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS) | completed | Phase 1 | 63 | Infinity Pharmaceuticals, Inc.INDUSTRY | 2 | Jan 6, 2011 | clinicaltrials |
| NCT00069940 | Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor | completed | Phase 1 | — | Dana-Farber Cancer InstituteOTHER | 1 | Dec 28, 2010 | clinicaltrials |
| NCT00457743 | A Phase I/II Study of Sunitinib Malate (SU011248) In Patients With Gastrointestinal Stromal Tumor (GIST) | completed | Phase 1 / Phase 2 | 36 | PfizerINDUSTRY | 1 | Nov 13, 2009 | clinicaltrials |
| NCT00041808 | Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver | completed | Phase 1 / Phase 2 | 20 | FeRxINDUSTRY | 2 | Jun 24, 2005 | clinicaltrials |
Data updated 23 days agoSource updated Oct 1, 2014source: clinicaltrials